Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Successful Drill Program at Nevada Gold Project points toward Mine Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more

Recent & Breaking News (NDAQ:ACAD)

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease Psychosis

Business Wire November 27, 2023

Acadia Pharmaceuticals Announces Change in Research and Development Leadership

Business Wire November 21, 2023

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 14, 2023

Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview

Business Wire November 2, 2023

Acadia Pharmaceuticals to Participate in the Guggenheim Securities 5th Annual Inflammation & Immunology Conference

Business Wire October 31, 2023

Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program

Business Wire October 23, 2023

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023

Business Wire October 19, 2023

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 18, 2023

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 22, 2023

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

Business Wire September 19, 2023

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire August 30, 2023

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Lawsuit Against Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) and Encourages Long-Term ACAD Investors to Contact the Firm

PR Newswire August 16, 2023

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 14, 2023

Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview

Business Wire August 2, 2023

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 1, 2023

Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer

Business Wire July 24, 2023

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023

Business Wire July 19, 2023

Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren's NNZ-2591 in Rett Syndrome and Fragile X Syndrome

Business Wire July 13, 2023

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 26, 2023

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome

Business Wire June 13, 2023